Influence of abnormal spleen on liver pathophysiological function in patients with liver cirrhosis

Jiang XiaoNi; Liu Min; Li Qiang; Wang YuPing; Guo QingHong; Guan QuanLin; Zhou YongNing

doi:10.3969/j.issn.1001-5256.2018.11.034

Issue 11

Nov. 2018

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2018 > 34(11): 2420-2422

PDF( 1594 KB)

Influence of abnormal spleen on liver pathophysiological function in patients with liver cirrhosis

DOI: 10.3969/j.issn.1001-5256.2018.11.034

Research funding:

Published Date: 2018-11-20

Abstract

Abstract

Splenomegaly is an early sign of cirrhotic portal hypertension. In patients with liver cirrhosis, the resistance of splenic venous reflux increases and portal venous pressure is reversed to the spleen, which causes congestive splenomegaly and hyperplasia of splenic tissue and fibrous tissue. In addition, intestinal antigens enter the systemic circulation via the portal-systemic collateral circulation and stimulates the proliferation of mononuclear macrophages in the spleen after being taken up by the spleen, which further leads to splenomegaly and hypersplenism. On the contrary, abnormal spleen can cause the changes in liver function and portal vein hemodynamics. Therefore, the intervention of the spleen cannot be neglected during the treatment of liver cirrhosis and its complications. This article reviews the influence of abnormal spleen structure and function on liver pathophysiological function in patients with liver cirrhosis.
- liver cirrhosis,
- hypertension, portal,
- splenomegaly,
- hypersplenism,
- review

FullText(HTML)

References(37)

References

[1] MCKENZIE CV, COLONNE CK, YEO JH, et al. Splenomegaly:Pathophysiological bases and therapeutic options[J]. Int J Biochem Cell B, 2018, 94:40-43.

[2] LI H, WANG GS. Research progress in hypersplenism after liver transplantation for liver cirrhosis[J]. Ogran Transplantation, 2016, 7 (3) :238-240. (in Chinese) 李慧, 汪根树.肝硬化肝移植术后脾功能亢进的研究进展[J].器官移植, 2016, 7 (3) :238-240.

[3] OKUDA K, KONG K, OHNISHI K, et al. Clinical study of eightysix caseins of idiopathic portal hypertension and comparison with cirrhosis with splenomegaly[J]. Gasteoenterology, 1984, 86:600-610.

[4] PRESSER N, QUONTINI C, TOM C, et al. Safety and efficacy of splenic artery embolization for portal hyperperfusion in liver transplant recipients:A 5-year experience[J]. Liver Transplant, 2015, 21 (4) :435-441.

[5] LI YN, MIAO XY, QI HZ, et al. Splenic artery trunk embolization reduces the surgical risk of liver transplantation[J]. Hepatobiliary Pancreat Dis Int, 2015, 14 (3) :263-268.

[6] TSOCHATZIS EA, BOSCH J, BURROUGHS AK. Liver cirrhosis[J]. Lancet, 2014, 383 (9930) :1749-1761.

[7] VAIRAPPAN B. Endothelial dysfunction in cirrhosis:Role of inflammation and oxidative stress[J]. World J Hepatol, 2015, 7 (3) :443-459.

[8] BOLOGNESI M, PASCOLI MD, VERARDO A, et al. Splanchnic vasodilation and hyperdynamic circulatory syndrome in cirrhosis[J].World J Gastroenterol, 2014, 20 (10) :2555-2563.

[9] NAGASUE N, DHAR DK, YAMANOI A, et al. Production and release of endothelin-1 from the gut and spleen in portal hypertension due to cirrhosis[J]. Hepatology, 2000, 31 (5) :1107-1114.

[10] MITCHELL O, FELDMAN DM, DIAKOW M, et al. The pathophysiology of thrombocytopenia in chronic liver disease[J]. Hepat Med, 2016, 8 (1) :39-50.

[11] HAYASHI H, BEPPU T, SHIRABE K, et al. Management of thrombocytopenia due to liver cirrhosis:A review[J]. World J Gastroenterol, 2014, 20 (10) :2595-2605.

[12] MASSOUD OI, ZEIN NN. The effect of transjugular intrahepatic portosystemic shunt on platelet counts in patients with liver cirrhosis[J].Gastroenterol Hepatol, 2017, 13 (5) :286-291.

[13] CHIEN CH, LIN YL, CHIEN RN, et al. Transient elastography for spleen stiffness measurement in patients with cirrhosis:Role in degree of thrombocytopenia[J]. J Ultras Med, 2016, 35 (9) :1849-1857.

[14] DUBOIS B, WILCOX C, WEINTRAUB J, et al. Efficacy and safety of partial splenic embolization in patients with splenomegaly associated cytopenias[J]. J Vasc Interv Radiol, 2017, 28 (2) :s69-s70.

[15] FEND B, ZHANG W, LUO BF, et al. Effect of spleen operation on antiviral treatment in hepatitis C virus-related cirrhotic patients[J].World J Gastroenterol, 2014, 20 (41) :15387-15397.

[16] PRIMIGNANI M. Portal vein thrombosis, revisited[J]. Digest Liver Dis, 2010, 42:163-170.

[17] QI XS, STEFANO VD. Anticoagulation for thetreatment of portal vein thrombosis in liver cirrhosis:A systematic review and meta-analysis of observational studies[J]. Eur J Intern Med, 2015, 26 (1) :23-29.

[18] PU YS, ZHANG S, ZHOU R, et al. IL-17A up-regulates expression of endothelial tissue factor in liver cirrhosis via the ROS/p38 signal pathway[J]. Biochem Biophys Res Commun, 2016, 470 (1) :41-47.

[19] ORLANDO R, LIRUSSI F, BASSO SM, et al. Splenomegaly as risk factor of liver cirrhosis. A retrospective cohort study of 2, 525patients who underwent laparoscopy[J]. Vivo, 2011, 25 (23) :1009-1012.

[20] WANG LF, SUN Y, ZHANG Z, et al. CXCR5+CD4+T follicular helper cells participate in the pathogenesis of primary biliary cirrhosis[J]. Hepatology, 2015, 61 (2) :627-638.

[21] LI L, DUAN M, CHEN W, et al. The spleen in liver cirrhosis:Revisiting an old enemy with novel targets[J]. J Transl Med, 2017, 15 (1) :111.

[22] ABOU-SHADY M, FRIESS H, ZIMMERMANN A, et al. Connective tissue growth factor in human liver cirrhosis[J]. Liver, 2000, 20 (4) :296-304.

[23] KUROKAWA T, OHKOHCHI N. Platelets in liver disease, cancer and regeneration[J]. World J Gastroenterol, 2017, 23 (18) :3228-3239.

[24] AKAHOSHI T, HASHIZUME M, TANOUE K, et al. Role of the spleen in liver ftbrosis in rats may be mediated by transforming growth factorβ-1[J]. J Gastroen Hepatol, 2002, 17 (1) :59-65.

[25] KONG DG, CHEN XL, LU SC, et al. Short-term effects of splenectomy on serum fibrosis indexes in liver cirrhosis patients[J]. Int J Clin Exp Pathol, 2015, 8 (11) :15260-15264.

[26] KWON YJ, LEE KG, CHOI D. Clinical implications of advances in liver regeneration[J]. Clin Mol Hepatol, 2015, 21 (1) :7-13.

[27] YAMADA S, MORINE Y, IMURA S, et al. Liver regeneration after splenectomy in patients with liver cirrhosis[J]. Hepatol Res, 2016, 46 (5) :443-449.

[28] MEYER J, LEJMI E, FONTANA P, et al. A focus on the role of platelets in liver regeneration:Do platelet-endothelial cell interactions initiate the regenerative process?[J]. J Hepatol, 2015, 63 (5) :1263-1271.

[29] STARLINGER P, ASSINGER A, GRUENBERGER T, et al. The role of platelets and portal venous pressure fluctuations in postoperative liver regeneration[J]. Eur Surg, 2015, 47 (6) :312-318.

[30] UEDA S, YAMANOI A, HISHIKAWA Y, et al. Transforming growth factor-β1 released from the spleen exerts a growth inhibitory effect on liver regeneration in rats[J]. Lab Invest, 2003, 83 (11) :1595-1603.

[31] CARRAPITA J, ARANTES AM, CAMPELOS S, et al. Impact of splenic artery ligation after major hepatectomy on liver function, regeneration and viability[J]. Sci Rep, 2016, 6:34731.

[32] LIU G, XIE C, FANG Y, et al. Splenectomy after partial hepatectomy accelerates liver regeneration in mice by promoting tight junction formation via polarity protein par 3-a PKC[J]. Life Sci, 2018, 192:91-98.

[33] YAMAMOTO N, OKANO K, OSHIMA M, et al. Laparoscopic splenectomy for patients with liver cirrhosis:Improvement of liver function in patients with child-pugh class B[J]. Surgery, 2015, 158 (6) :1538-1544.

[34] CHIN JL, CHAN G, RYAN JD, et al. Spleen stiffness can noninvasively assess resolution of portal hypertension after liver transplantation[J]. Liver Int, 2015, 35 (2) :518-523.

[35] WONG GLH, KWOK R, HUI AJ, et al. A new screening strategy for varices by liver and spleen stiffness measurement (LSSM) in cirrhotic patients:A randomized trial[J]. Liver Int, 2018, 38 (4) :636-644.

[36] SONG JY, DU GS, XIAO L, et al. Individualized immunosuppressive protocol of liver transplant recipient should be made based on splenic function status[J]. Chin Med J, 2016, 129 (11) :1340-1346.

[37] GAO XQ, ZHAO YX, REN X, et al. Research advances in druginduced autoimmune hepatitis[J]. J Clin Hepatol, 2017, 33 (11) :2222-2225. (in Chinese) 高晓琴, 赵永勋, 任茜, 等.药物诱导的自身免疫性肝炎的研究进展[J].临床肝胆病杂志, 2017, 33 (11) :2222-2225.

Relative Articles

[1]	Haifeng LIU, Simin ZHOU, Jiwen LI, Jiangpeng LIU, Bangmao WANG, Lu ZHOU. Effect of depression on response to ursodeoxycholic acid and the occurrence of liver cirrhosis in patients with primary biliary cholangitis[J]. Journal of Clinical Hepatology, 2023, 39(12): 2817-2823. doi: 10.3969/j.issn.1001-5256.2023.12.011
[2]	Zhang JingQiao, Li MiaoMiao, Qi XingShun, Ceng QingLei, Jia JiDong. An excerpt of update on prevention, diagnosis, and treatment and of chronic hepatitis B: AASLD 2018 hepatitis B guidance[J]. Journal of Clinical Hepatology, 2018, 34(12): 2563-2567. doi: 10.3969/j.issn.1001-5256.2018.12.011
[3]	Zhang JingQiao, Li MiaoMiao, Qi XingShun, Ceng QingLei. An excerpt of update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance[J]. Journal of Clinical Hepatology, 2018, 34(4): 737-742. doi: 10.3969/j.issn.1001-5256.2018.04.009
[4]	Gao ShengLi, Zhao Gang, Xu MiQin, Shen Yan, Yu Jing, Ye Yang, He LiHua, Jin WenJuan, Sun GuiYing, Niu ZhiLin. Efficacy and safety of interferon-α given additionally or sequentially after long-term entecavir therapy in treatment of chronic hepatitis B[J]. Journal of Clinical Hepatology, 2018, 34(2): 268-271. doi: 10.3969/j.issn.1001-5256.2018.02.010
[5]	Wan MoBin. Individualized treatment with pegylated interferon-α for chronic hepatitis B[J]. Journal of Clinical Hepatology, 2018, 34(5): 930-933. doi: 10.3969/j.issn.1001-5256.2018.05.004
[6]	Ma XiQuan, Xiong WuJun, Liu Lu, Wang YiFei, Cheng Jie, Zhang ZhengXia, Zhao Hui, Qu LiHong. Current status of anxiety and depression among hepatitis B patients in Shanghai, China and related influencing factors[J]. Journal of Clinical Hepatology, 2018, 34(8): 1664-1668. doi: 10.3969/j.issn.1001-5256.2018.08.014
[7]	Tao JunXiu, Li XiaoDong, Cao Ting, Xiao MingZhong, Wu HuiKun, Wu Deng, Ren Meng, Wang Ting, Bai LiYing. A study of compliance in patients with HBeAg-negative chronic hepatitis B receiving entecavir treatment[J]. Journal of Clinical Hepatology, 2017, 33(8): 1558-1560. doi: 10.3969/j.issn.1001-5256.2017.08.030
[8]	Sun YaMeng, You Hong. Advances in staging and treatment of hepatitis B cirrhosis[J]. Journal of Clinical Hepatology, 2016, 32(6): 1036-1039. doi: 10.3969/j.issn.1001-5256.2016.06.003
[9]	Ning Ling, Sun Jian, Chen Nan, Hou JinLin. Renal safety in chronic hepatitis B patients treated with nucleos(t) ide analogues[J]. Journal of Clinical Hepatology, 2016, 32(5): 981-985. doi: 10.3969/j.issn.1001-5256.2016.05.042
[10]	Han BenLi. Clinical efficacy of entecavir in HBeAg-negative chronic hepatitis B with compensated cirrhosis[J]. Journal of Clinical Hepatology, 2016, 32(8): 1525-1528. doi: 10.3969/j.issn.1001-5256.2016.08.018
[11]	Xie YongCai, Hu GuoXin, Peng YanZhong, Zheng Jie, Li YinPing. Clinical effect of Dahuang Zhechong capsules combined with entecavir in treatment of chronic hepatitis B patients with liver fibrosis[J]. Journal of Clinical Hepatology, 2016, 32(8): 1502-1507. doi: 10.3969/j.issn.1001-5256.2016.08.014
[12]	Hu XiaoYun, Sun Jian, Peng Jie. New considerations in antiviral therapy for special populations with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2016, 32(11): 2054-2057. doi: 10.3969/j.issn.1001-5256.2016.11.007
[13]	Chinese Society of Hepatology, Chinese Medical Association. Expert consensus on antiviral therapy for chronic hepatitis B with renal injury or high risk of renal injury[J]. Journal of Clinical Hepatology, 2016, 32(12): 2242-2247. doi: 10.3969/j.issn.1001-5256.2016.12.004
[14]	Gao YanHang, Liu PeiYan, Gao PuJun. Advances in research and development of new drugs for antiviral therapy for chronic hepatitis B[J]. Journal of Clinical Hepatology, 2016, 32(11): 2043-2049. doi: 10.3969/j.issn.1001-5256.2016.11.005
[15]	Zhu DongLiang, Li DaoBo, Zhao ManZhi, Ma Ke, Song JianXin, Xu Dong. Clinical effect of entecavir in treatment of patients with chronic hepatitis B complicated by tuberculosis[J]. Journal of Clinical Hepatology, 2016, 32(11): 2084-2087. doi: 10.3969/j.issn.1001-5256.2016.11.014
[16]	Wang QingHai, Luo KaiZhong, Tian Yi. Effect and safety of bilirubin serum adsorption in treatment of patients with chronic severe hepatitis B[J]. Journal of Clinical Hepatology, 2016, 32(7): 1296-1299. doi: 10.3969/j.issn.1001-5256.2016.07.016
[17]	Yang XiaoYan, Sun ZhangYu, Yuan Xiang, Liang YaLin. Clinical analysis of hypophosphatemia induced by adefovir dipivoxil in treatment of chronic hepatitis B[J]. Journal of Clinical Hepatology, 2015, 31(12): 2047-2050. doi: 10.3969/j.issn.1001-5256.2015.12.014
[18]	Zhu ShiShu, Zhang HongFei. Antiviral therapy of chronic hepatitis B in children[J]. Journal of Clinical Hepatology, 2015, 31(8): 1211-1214. doi: 10.3969/j.issn.1001-5256.2015.08.007
[19]	Yan Jie, Xie Wen. Expert consenus on antiviral therapy for special patients with chronic hepatitis B: an update in 2014[J]. Journal of Clinical Hepatology, 2014, 30(7): 580-587. doi: 10.3969/j.issn.1001-5256.2014.07.002
[20]	Liao YunFan, Jia-Horng Kao, Teerha Piratvisuth, et al. Asian-pacific consensus statement on the management of chronic hepatitis B: a 2012 update[J]. Journal of Clinical Hepatology, 2012, 28(8): 641-661.

Supplements(0)

Cited By

Cited by

Periodical cited type(20)

1.	王勇，倪雷，闫波，司运飞. 规则性肝段切除在肝内胆管结石患者中的应用. 贵州医药. 2021(07): 1154-1155 .
2.	蒋增强，石耀. 解剖性肝切除术治疗60岁以下肝胆管结石患者的临床效果观察. 临床研究. 2020(02): 54-55 .
3.	朱景波. 腹腔镜胆道探查取石术治疗肝内外胆管结石的效果观察. 临床医学. 2020(05): 75-77 .
4.	黄春雷，廖朝兴. 超声引导下PTCD治疗治疗恶性梗阻性黄疸的临床疗效及安全性分析. 实用心脑肺血管病杂志. 2020(S1): 83-85 .
5.	侯勇，李克志，王永平，张宏. 解剖性肝切除术与非规则性肝切除术治疗肝内胆管结石效果分析. 中国继续医学教育. 2019(06): 92-94 .
6.	王金宝，谭庆娟，王维山，刘成彪，孙启栋. 腹腔镜肝段切除术治疗左肝胆管结石的随机对照研究. 腹腔镜外科杂志. 2019(05): 356-359 .
7.	倪颖，贺登秀，徐滔. 自拟中药方结合腹腔镜联合胆道镜手术治疗肝内外胆管结石疗效观察. 四川中医. 2019(07): 113-116 .
8.	郭威，张冲，李桂鲜，吴嘉兴，蒋建晖，姚红兵. 解剖性肝切除在严重肝外伤手术中的应用. 河北医科大学学报. 2019(09): 1034-1037 .
9.	辛大平，彭彬，黄明，黄纪伟. 精准肝切除与非规则性肝切除治疗肝内胆管结石效果比较. 郑州大学学报(医学版). 2019(05): 762-765 .
10.	白庆鹤. 精准肝切除术与非规则性肝切除术治疗肝内胆管结石临床效果对比. 临床合理用药杂志. 2019(34): 149-150 .
11.	吴忠寅，丁锐. 左肝蒂阻断左半肝切除术在肝内胆管结石中应用临床观察. 创伤与急危重病医学. 2018(04): 235-236 .
12.	许长涛，郑方，王瑞官，李为民. 胆管结石性黄疸患者围术期内调节性T细胞免疫功能变化临床研究. 临床军医杂志. 2018(08): 865-868 .
13.	王新团，李山林，耿智敏. 腹腔镜与开腹肝切除术治疗区域型肝胆管结石病的倾向性评分匹配研究. 临床肝胆病杂志. 2018(03): 531-534 . 本站查看
14.	皇甫行勋. 腹腔镜解剖性肝左外叶切除术治疗肝内胆管结石. 牡丹江医学院学报. 2018(04): 64-65+90 .
15.	辛莘，郐大余，徐宝宏. ERCP、十二指肠乳头小切开联合乳头括约肌气囊扩张术在肝外胆管结石治疗中的临床应用. 中国医刊. 2018(04): 388-389 .
16.	唐梅，巫强，龙洪航，熊雪娇. 解剖性肝切除术与非规则性肝切除术治疗肝内胆管结石效果分析. 北华大学学报(自然科学版). 2018(03): 367-370 .
17.	周建平，许平平，贺小武，谢鹏，王立. CT诊断与外科治疗在严重闭合性肝外伤救治中应用价值研究. 临床军医杂志. 2018(10): 1233-1234 .
18.	周龙飞，朱鸿超，刘洪亮，黄明文. 腹腔镜肝切除术在肝胆管结石治疗中的应用. 中华肝脏外科手术学电子杂志. 2018(05): 371-374 .
19.	李留峥，徐雷升，俸家伟，王志萍，高学昌，龚国茶，敖强，于杰. 解剖性肝切除术治疗复杂肝内胆管结石体会. 腹部外科. 2017(06): 456-459+463 .
20.	李留峥，徐雷升，俸家伟，王志萍，高学昌，龚国茶，敖强，于杰. Glisson蒂横断式解剖性肝切除120例治疗体会. 肝胆胰外科杂志. 2017(05): 359-362+367 .

Other cited types(2)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (1811) PDF downloads(353)

Influence of abnormal spleen on liver pathophysiological function in patients with liver cirrhosis

DOI: 10.3969/j.issn.1001-5256.2018.11.034